Genzyme Corporation – Product Pipeline Review

Global Markets Direct’s, ‘Genzyme Corporation – Product Pipeline Review – 2016’, provides an overview of the Genzyme Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genzyme Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Genzyme Corporation

The report provides overview of Genzyme Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Genzyme Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Genzyme Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Genzyme Corporation’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Genzyme Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Genzyme Corporation’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Genzyme Corporation Snapshot 6

Genzyme Corporation Overview 6

Key Information 6

Key Facts 6

Genzyme Corporation - Research and Development Overview 7

Key Therapeutic Areas 7

Genzyme Corporation - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Genzyme Corporation - Pipeline Products Glance 14

Genzyme Corporation - Late Stage Pipeline Products 14

Phase III Products/Combination Treatment Modalities 14

Genzyme Corporation - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Genzyme Corporation - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Genzyme Corporation - Drug Profiles 19

patisiran 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

revusiran 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

sargramostim 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

vandetanib 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

GZ-402666 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

olipudase alfa 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ibiglustat 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

GZ-402668 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

VYAADC-01 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

1D-11 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

GENZ-644442 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules for Malaria 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Genzyme Corporation - Pipeline Analysis 41

Genzyme Corporation - Pipeline Products by Target 41

Genzyme Corporation - Pipeline Products by Route of Administration 43

Genzyme Corporation - Pipeline Products by Molecule Type 44

Genzyme Corporation - Pipeline Products by Mechanism of Action 45

Genzyme Corporation - Recent Pipeline Updates 46

Genzyme Corporation - Dormant Projects 59

Genzyme Corporation - Discontinued Pipeline Products 61

Discontinued Pipeline Product Profiles 61

GZ-402674 61

GZ-404477 61

tasidotin hydrochloride 61

teriflunomide 61

tolevamer potassium sodium 61

vandetanib 62

Genzyme Corporation - Locations and Subsidiaries 63

Head Office 63

Other Locations & Subsidiaries 63

Genzyme Corporation - Key Manufacturing Facilities 72

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

List of Tables

Genzyme Corporation, Key Information 6

Genzyme Corporation, Key Facts 6

Genzyme Corporation – Pipeline by Indication, 2016 8

Genzyme Corporation – Pipeline by Stage of Development, 2016 10

Genzyme Corporation – Monotherapy Products in Pipeline, 2016 11

Genzyme Corporation – Partnered Products in Pipeline, 2016 12

Genzyme Corporation – Partnered Products/ Combination Treatment Modalities, 2016 13

Genzyme Corporation – Phase III, 2016 14

Genzyme Corporation – Phase II, 2016 15

Genzyme Corporation – Phase I, 2016 16

Genzyme Corporation – Preclinical, 2016 17

Genzyme Corporation – Discovery, 2016 18

Genzyme Corporation – Pipeline by Target, 2016 42

Genzyme Corporation – Pipeline by Route of Administration, 2016 43

Genzyme Corporation – Pipeline by Molecule Type, 2016 44

Genzyme Corporation – Pipeline Products by Mechanism of Action, 2016 45

Genzyme Corporation – Recent Pipeline Updates, 2016 46

Genzyme Corporation – Dormant Developmental Projects,2016 59

Genzyme Corporation – Discontinued Pipeline Products, 2016 61

Genzyme Corporation, Other Locations 63

Genzyme Corporation, Subsidiaries 69

Genzyme Corporation, Key Manufacturing Facilities 72

List of Figures

List of Figures

Genzyme Corporation – Pipeline by Top 10 Indication, 2016 8

Genzyme Corporation – Pipeline by Stage of Development, 2016 10

Genzyme Corporation – Monotherapy Products in Pipeline, 2016 11

Genzyme Corporation – Partnered Products in Pipeline, 2016 12

Genzyme Corporation – Pipeline by Top 10 Target, 2016 41

Genzyme Corporation – Pipeline by Route of Administration, 2016 43

Genzyme Corporation – Pipeline by Molecule Type, 2016 44

Genzyme Corporation – Pipeline Products by Top 10 Mechanism of Action, 2016 45

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports